Invuity, Inc. (IVTY) Reaches $3.40 52-Week Low; Montag A & Associates Has Trimmed By $491,760 Its Cvs Health Corp. (CVS) Stake

April 27, 2018 - By wolcottdaily

Invuity, Inc. (NASDAQ:IVTY) Logo

Montag A & Associates Inc decreased Cvs Health Corp. (CVS) stake by 15.46% reported in 2017Q4 SEC filing. Montag A & Associates Inc sold 6,830 shares as Cvs Health Corp. (CVS)’s stock declined 17.45%. The Montag A & Associates Inc holds 37,337 shares with $2.71 million value, down from 44,167 last quarter. Cvs Health Corp. now has $71.06 billion valuation. The stock increased 1.76% or $1.21 during the last trading session, reaching $69.9. About 4.24M shares traded. CVS Health Corporation (NYSE:CVS) has declined 22.81% since April 27, 2017 and is downtrending. It has underperformed by 34.36% the S&P500.

The stock of Invuity, Inc. (NASDAQ:IVTY) hit a new 52-week low and has $3.30 target or 3.00% below today’s $3.40 share price. The 9 months bearish chart indicates high risk for the $79.49 million company. The 1-year low was reported on Apr, 27 by Barchart.com. If the $3.30 price target is reached, the company will be worth $2.38 million less. The stock decreased 2.86% or $0.1 during the last trading session, reaching $3.4. About 108,223 shares traded. Invuity, Inc. (NASDAQ:IVTY) has declined 54.52% since April 27, 2017 and is downtrending. It has underperformed by 66.07% the S&P500.

Investors sentiment decreased to 0.72 in Q4 2017. Its down 0.16, from 0.88 in 2017Q3. It dropped, as 115 investors sold CVS shares while 600 reduced holdings. 134 funds opened positions while 380 raised stakes. 815.59 million shares or 1.76% more from 801.45 million shares in 2017Q3 were reported. Hills Financial Bank & has invested 0.94% in CVS Health Corporation (NYSE:CVS). Lloyds Group Public Ltd Com invested 1.35% of its portfolio in CVS Health Corporation (NYSE:CVS). Liberty reported 1.34% of its portfolio in CVS Health Corporation (NYSE:CVS). Carret Asset Mgmt holds 1.08% of its portfolio in CVS Health Corporation (NYSE:CVS) for 95,319 shares. 1832 Asset LP owns 38,703 shares for 0.01% of their portfolio. Lvm Cap Mngmt Ltd Mi holds 0.07% or 4,510 shares. Barclays Public Limited Company owns 2.30 million shares for 0.14% of their portfolio. Bokf Na stated it has 0.1% in CVS Health Corporation (NYSE:CVS). Pub Sector Pension Invest Board owns 113,479 shares for 0.05% of their portfolio. Tokio Marine Asset Mgmt reported 5,888 shares. The Indiana-based First Finance Corporation In has invested 0.12% in CVS Health Corporation (NYSE:CVS). Chicago Equity Limited Company holds 83,375 shares or 0.18% of its portfolio. Gam Hldgs Ag stated it has 68,899 shares. Westpac Banking holds 66,195 shares. Sentry Invs Corp has 4.30M shares.

Since February 16, 2018, it had 0 insider purchases, and 1 sale for $1.42 million activity. 19,965 shares were sold by Foulkes Helena, worth $1.42M.

Montag A & Associates Inc increased Intel Corp (NASDAQ:INTC) stake by 225,417 shares to 306,255 valued at $14.14 million in 2017Q4. It also upped Ishares Nasdaq Biotech Etf (IBB) stake by 12,420 shares and now owns 19,155 shares. Raytheon Co (NYSE:RTN) was raised too.

Analysts await CVS Health Corporation (NYSE:CVS) to report earnings on May, 2 before the open. They expect $1.40 EPS, up 19.66% or $0.23 from last year’s $1.17 per share. CVS’s profit will be $1.42 billion for 12.48 P/E if the $1.40 EPS becomes a reality. After $1.92 actual EPS reported by CVS Health Corporation for the previous quarter, Wall Street now forecasts -27.08% negative EPS growth.

Among 26 analysts covering CVS Health (NYSE:CVS), 19 have Buy rating, 0 Sell and 7 Hold. Therefore 73% are positive. CVS Health had 76 analyst reports since July 22, 2015 according to SRatingsIntel. The company was maintained on Monday, December 4 by Needham. Citigroup maintained the shares of CVS in report on Thursday, August 17 with “Neutral” rating. Robert W. Baird maintained CVS Health Corporation (NYSE:CVS) on Thursday, February 8 with “Hold” rating. The rating was maintained by Needham with “Buy” on Tuesday, January 2. The rating was upgraded by Raymond James to “Buy” on Thursday, January 4. Leerink Swann maintained it with “Buy” rating and $85.0 target in Tuesday, November 21 report. As per Wednesday, August 19, the company rating was reinitiated by Evercore. The firm earned “Overweight” rating on Monday, November 2 by JP Morgan. Jefferies maintained it with “Hold” rating and $86 target in Friday, September 15 report. The rating was maintained by Robert W. Baird on Monday, September 25 with “Hold”.

Invuity, Inc., a medical technology company, develops various surgical devices to address various surgical procedures in the United States. The company has market cap of $79.49 million. The firm integrates its intelligent photonics technology platform into its single-use and reusable advanced surgical devices to address various critical intracavity illumination and visualization challenges. It currently has negative earnings. It offers various illuminated surgical devices, including Eikon LT Illuminated and Eikon illuminated retractor systems for breast oncology/oncoplastic/general/orthopedics surgeries; Saber Yankauer, a handheld illuminator for orthopedic/spine/cardiothoracic/breast/general surgeries; and Saber Frazier, a handheld illuminator for spine/orthopedic/neurosurgery surgeries.

Among 5 analysts covering Invuity Inc (NASDAQ:IVTY), 5 have Buy rating, 0 Sell and 0 Hold. Therefore 100% are positive. Invuity Inc has $25 highest and $6.0 lowest target. $12’s average target is 252.94% above currents $3.4 stock price. Invuity Inc had 8 analyst reports since August 29, 2016 according to SRatingsIntel. The stock of Invuity, Inc. (NASDAQ:IVTY) has “Buy” rating given on Monday, August 29 by Craig Hallum. The stock of Invuity, Inc. (NASDAQ:IVTY) has “Buy” rating given on Monday, September 19 by Lake Street. The company was maintained on Wednesday, February 14 by Stifel Nicolaus. As per Wednesday, July 26, the company rating was maintained by Northland Capital. Piper Jaffray maintained the shares of IVTY in report on Tuesday, July 25 with “Buy” rating. Northland Capital maintained Invuity, Inc. (NASDAQ:IVTY) rating on Tuesday, June 13. Northland Capital has “Buy” rating and $1300 target.

CVS Health Corporation (NYSE:CVS) Institutional Positions Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our daily email newsletter.





Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our free daily email newsletter: